<DOC>
	<DOCNO>NCT02515734</DOCNO>
	<brief_summary>This study verify advantage FOLFOXIRI plus cetuximab FOLFOXIRI plus bevacizumab first-line therapy metastatic colorectal cancer patient RAS wild-type tumor .</brief_summary>
	<brief_title>A Study FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab</brief_title>
	<detailed_description>This study verify advantage FOLFOXIRI plus cetuximab FOLFOXIRI plus bevacizumab first-line therapy metastatic colorectal cancer patient RAS wild-type tumor . In study investigator employ deepness response primary endpoint .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm colorectal cancer RAS wildtype Measurable lesion RECIST ( Ver.1.1 ) No past history chemotherapy case unresectable primary lesion/distant metastasis/lymph node metastasis.In case recurrence , treatment first recurrence lesion operation Eastern Cooperative Oncology Group ( ECOG ) Performance status 01.The case &gt; =71 year PS0 . Life expectancy 6 month Patients enough organ function study treatment within 14 day enrollment ; 1 . White blood cell ( WBC ) &gt; =3,000/mm3 , &lt; 12,000/mm3 . 2 . Neu &gt; =1,500/mm3 . 3 . Platelet count ( PLT ) &gt; =10.0x104/mm3 . 4 . Hb &gt; =9.0g/dL . 5 . Total Bilirubin &lt; =1.5x Upper Limited Normal ( ULN ) 6. aspartate aminotransferase ( AST ) &lt; =2.5xULN . 7. alanine aminotransferase ( ALT ) &lt; =2.5xULN . 8 . Creatinine &lt; =1.5xULN . 9 . Proteinuria &lt; =1+ . 10. prothrombin timeinternational normalize ratio ( PTINR ) &lt; =1.5 Must able swallow tablet Written inform consent Synchronous multiple malignancy metachronous multiple malignancy within 5 year disease free interval Lynch syndrome Brain metastases Infectious disease Interstitial lung disease pulmonary fibrosis Comorbidity history serious heart failure History thromboembolic event Cerebrovascular disease History hemoptysis/hematemesis Uncontrolled hypertension ( systolic BP &gt; 180mmHg , diastolic BP &gt; 100mmHg ) Sensory alteration paresthesia interfere function Large quantity pleural , abdominal cardiac effusion Severe comorbidity ( renal failure , liver failure , hypertension , etc ) Prior radiotherapy primary metastasis leision Men/women unwilling avoid pregnancy Women pregnant breastfeed Women positive pregnancy test History severe allergy HBsAg positive active viral hepatitis Administration blood products/ GranulocyteColony Stimulating Factor ( GCSF ) , blood transfusion within 14 day Surgical procedure skinopen biopsy , trauma surgery , intensive surgery within 28 day Systematic administration antiplatelet drug non steroid antiinflammatory drug ( NSAIDs ) Diathesis bleeding ( history hemoptysis , include cavitation and/or necrosis lung metastasis confirm image ) , coagulopathy History gastrointestinal perforation within 1 year Unhealed traumatic bone fracture Uncontrolled diarrhea History organ recipient Prior cetuximab/bevacizumab/Irinotecan/Oxaliplatin treatment ( Adjuvant therapy Oxaliplatin exclude ) Administration atazanavir sulfate Jaundice Ileus bowel obstruction Clinical diagnosis Alzheimer 's Disease Insulin dependent diabetes Thyroid disease Any case regard inadequate study enrollment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>FOLFOXIRI</keyword>
	<keyword>Bmab</keyword>
	<keyword>Cmab</keyword>
</DOC>